Please login to the form below
hematology
This page shows the latest hematology news and features for those working in and with pharma, biotech and healthcare.
J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma
Johnson &Johnson’s CD38 monoclonal antibody (mAb) Darzalex has achieved ‘significant’ overall survival (OS) data in newly diagnosed multiple myeloma, the company revealed at the European Hematology Association 2021 virtual congress
Latest news
-
Novartis’ iptacopan scores positive results in rare blood disorder PNH
According to the data, presented at the European Hematology Association 2021 virtual congress (EHA), treatment with 12 weeks of iptacopan was generally well tolerated and led to ‘rapid and durable’
-
BeiGene’s reveals positive data for Brukinsa in head-to-head Imbruvica trial
The results from an interim analysis of the trial, presented at the European Hematology Association 2021 (EHA2021) virtual congress, were based on the first 415 patient enrolled in the study.
-
bluebird bio presents new data for beti-cel in beta thalassemia at EHA2021
bluebird bio has presented new data for its gene therapy betibeglogene autotemcel (beti-cel) at the European Hematology Association 2021 virtual congress (EHA) in transfusion dependent beta thalassemia (TDT). .
-
BMS, Acceleron’s Reblozyl shows new improvements for beta thalassemia patients
The data, presented at the European Hematology Association (EHA) 2021 virtual congress, demonstrated that 77% of patients treated with Reblozyl (luspatercept-aamt) achieved a haemoglobin increase compared to 0% in the ... non-transfusion dependent
-
ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more
A round-up of some of the key data from the annual American Society of Hematology (ASH) meeting. ... It was a bumper year at the annual American Society of Hematology (ASH) meeting, with a slew of new data presented across the board.
Novartis’ iptacopan scores positive results in rare blood disorder PNH
BeiGene’s reveals positive data for Brukinsa in head-to-head Imbruvica trial
bluebird bio presents new data for beti-cel in beta thalassemia at EHA2021
BMS, Acceleron’s Reblozyl shows new improvements for beta thalassemia patients
ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more
More from news
Approximately 6 fully matching, plus 57 partially matching documents found.
Latest Intelligence
-
Attracting doctors to low-demand specialties
A brief glance at the programme for the major US haematology congress, held by the American Society of Hematology, tells its own story, with most sessions being dedicated to haematological malignancies
-
Deal Watch November 2016
This does not typically include royalty payments. 2. Ataga et al, Abstract, American Society of Hematology (ASH), December 2016.
-
Deal Watch July 2016
Portfolio of early-stage hematology candidates &option for recombinant pegasparaginase. Licence, option.
Attracting doctors to low-demand specialties
Deal Watch November 2016
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Nanobiotix strengthens US leadership team
Most recently, Dr Obrocea was AbbVie Biotherapeutics' project director and oncology clinical lead, overseeing a number of trials in oncology and hematology.
-
TxCell appoints global scientific advisory board
Prof Chiara Bonini (pictured left) is currently head of the experimental hematology unit at the San Raffaele Scientific Institute, a position she has held since 2008.
Nanobiotix strengthens US leadership team
TxCell appoints global scientific advisory board
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians. In this customer story, we summarize the outcomes from an ongoing project where our client is leveraging a variety of Impetus
-
Highlights in haematologic malignancy from ASH 2018
Earlier this month, Porterhouse Medical attended the 60. th. American Society of Hematology (ASH) Annual Meeting (). The ASH congress is the most comprehensive haematology event of the year, attracting 25, 000
-
Random42 Attending ASH Annual Meeting in San Diego
Now in its 60th year the American Society of Hematology (ASH) annual meeting and exposition is the premier event in malignant and non-malignant hematology. ... The meeting provides an invaluable educational experience and the opportunity to review
-
Increasing the speed of knowledge sharing in blood cancer to improve patient care
Society of Hematology XXXVI World Congress in Congress ( ISH), which was hosted by the British Society for Haematology at the 56th Annual Scientific Meeting, between 18th-21st April.
-
Lighthouse Medical Communications US bolster their senior scientific team
number of key therapeutic areas such endocrinology, neurology, oncology, hematology, women’s health and rare diseases.
More from PMHub
Approximately 3 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
-
CEO Pricing & Market Access, UK
-
Six figure salary
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- Embattled Biogen talks up Aduhelm
- David Hunt launches independent agency The Considered
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- New data from Moderna supports COVID boosters
- $47.5m research centre to seek genetic insights into disease
- Havas Life Medicom and ARK lead at 2021 PM Society Digital Awards
- Nicky Hutchens appointed as deputy managing director at Four Health
- Health For All
- Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost
No results were found
PMHub
3 Monkeys Zeno
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...
Latest intelligence
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
- How to pick the perfect training program for your healthcare professionals
- You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...
